Skip to main content
Home
Main navigation
  • Who we are
  • Research
  • Guidelines
  • Stories
  • News
  • Support us
  • Contact us
  • Register

Latest news and
publications

Pulmonary sarcoidosis treatment efzofitimod Phase 3 trial to go on

A global Phase 3 clinical trial evaluating efzofitimod

8 Jan, 2025
Laboratory graphic
MRFF – Clinical Trials Activity Initiative - 2023 Clinical Trials Activity Grant Opportunity (GO6540)

SARI has submitted a proposal for funding to:

5 Jun, 2024
Hybrid Magnetic Resonance Positron Emission Tomography Is Associated With Cardiac-Related Outcomes in Cardiac Sarcoidosis.
Novel use of new hybrid PET/MRI imaging modality

Hybrid Magnetic Resonance Positron Emission Tomography Is Associated With Cardiac-Related Outcomes in Cardiac Sarcoidosis.

6 Feb, 2024
SARI board group image
Press Release: SARI – Sarcoidosis Advocacy and Research Initiative at UNSW Sydney

Sarcoidosis is a little-known condition that may attack virtually every organ in the body, is very difficult to diagnose and

1 Dec, 2023
Boehringer Ingelheim
Press Release: FDA Grants Ofev® Breakthrough Therapy Designation for Chronic Fibrosing ILDs with a Progressive Phenotype

On October 10, 2019, Boehringer Ingelheim announced that the US Food and Drug Administration (FDA) granted Breakthrough Th

5 Jun, 2023

To read more, visit the Sarcoidosis news website

Link
Read more
Footer
  • What is Sarcoidosis
  • Who we are
  • Research
  • Stories
  • News
  • Support us
  • Contact us
  • Register
  • Privacy statement
Secondary Footer
  • © 2023 SARI Ltd
  • Copyright & Disclaimer
  • Privacy